Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls.
about
Nanomedicine in the application of uveal melanomaPromiscuous tumor targeting phage proteins.An MRI-based classification scheme to predict passive access of 5 to 50-nm large nanoparticles to tumors.A Retrospective 30 Years After Discovery of the Enhanced Permeability and Retention Effect of Solid Tumors: Next-Generation Chemotherapeutics and Photodynamic Therapy--Problems, Solutions, and Prospects.Strategies to stabilize cell penetrating peptides for in vivo applications.HPMA Copolymer-Drug Conjugates with Controlled Tumor-Specific Drug Release.Radiolabelled Polymeric Materials for Imaging and Treatment of Cancer: Quo Vadis?Regulating the anticancer properties of organometallic dendrimers using pyridylferrocene entities: synthesis, cytotoxicity and DNA binding studies.Styrene-maleic acid-copolymer conjugated zinc protoporphyrin as a candidate drug for tumor-targeted therapy and imaging.Vascular targeting of nanoparticles for molecular imaging of diseased endothelium.Optical properties of biomimetic probes engineered from erythrocytes.Supramolecular Hydrogel from Nanoparticles and Cyclodextrins for Local and Sustained Nanoparticle Delivery.Nanotechnology for photodynamic therapy: a perspective from the Laboratory of Dr. Michael R. Hamblin in the Wellman Center for Photomedicine at Massachusetts General Hospital and Harvard Medical School.Antibody or Antibody Fragments: Implications for Molecular Imaging and Targeted Therapy of Solid TumorsSkin-derived mesenchymal stem cells as quantum dot vehicles to tumors.Polymer therapeutics and the EPR effect.Particle Targeting in Complex Biological Media.Tumor-associated macrophages, nanomedicine and imaging: the axis of success in the future of cancer immunotherapy.Silk nanoparticles: proof of lysosomotropic anticancer drug delivery at single-cell resolution.Supramolecular hydrogel based on high-solid-content mPECT nanoparticles and cyclodextrins for local and sustained drug delivery.Double Sequential Encrypted Targeting Sequence: A New Concept for Bone Cancer Treatment.When Is It Important to Measure Unbound Drug in Evaluating Nanomedicine Pharmacokinetics?The Interaction of CORM-2 with Block Copolymers Containing Poly(4-vinylpyridine): Macromolecular Scaffolds for Carbon Monoxide Delivery in Biological Systems.Analyses of repeated failures in cancer therapy for solid tumors: poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs.HPMA Copolymer-Conjugated Pirarubicin in Multimodal Treatment of a Patient with Stage IV Prostate Cancer and Extensive Lung and Bone Metastases.Considerations for clinically-relevant nanomedicine therapies for chronic diseasesPhotoluminescent polysaccharide-coated germanium(IV) oxide nanoparticlesImmunology, Immunotherapy, and Translating Basic Science into the Clinic for Bladder CancerToxicity Assessment of PEG-PCCL Nanoparticles and Preliminary Investigation on Its Anti-tumor Effect of Paclitaxel-LoadingPhotodynamic Therapy for Metastatic Melanoma Treatment: A ReviewLiposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response
P2860
Q28079572-CFD14A77-2419-426A-8325-CD0D62972A63Q36581309-FD175115-F08D-4A6D-B33C-77067FB1B45DQ36596242-51461FE2-3FF8-439E-A422-8508978DC944Q38559666-2982539A-90EC-4D88-A90C-846961B93370Q38602460-EE6FAF0E-9113-4059-8E88-3412BAE84E5DQ38626421-15F93E04-0BD1-48D5-BEE1-74F13101634DQ38755295-4F885989-1F35-4CE2-BED6-EE7E0B8E34F0Q38770155-19ECBBE4-6413-4198-A72E-0EC4204C6AC0Q38841235-E206638E-F326-4D24-B794-4E30FE166EB1Q38957484-425B799A-CDA6-42B7-9ECD-AF9F67F50F31Q39102733-F2ED12CF-B279-4E2C-AC4E-F1BD77A31589Q39829826-A88E5D3A-6F39-454D-A24D-00303A3FC4CCQ41823406-5E0B55A8-246A-44CB-9632-ACE57C9274E3Q42655550-40950D87-0928-4411-9573-46143267A08AQ47133839-087E38AC-1A0D-4226-BAC5-62EF23A74297Q47681427-142AA66C-CB94-4225-8FF4-1335A3607C91Q47794249-5654C3CE-26CC-4065-9CF6-2D08357D5B9BQ47962563-6DABA07E-5734-4862-A9A4-E6D1E920AF03Q48232569-C5E0773F-3B83-4971-9D59-F89E158D0231Q48254606-B5D4CDFF-E6D7-4C1D-9909-1C115C0F54ACQ48824485-E96E1869-7354-4B2B-A87C-0572A38CE3C4Q51460131-1156D5DB-E705-4A6E-BE38-AF760035CB4FQ51466931-C4809183-A949-463E-BF37-A74A0A050E70Q51763013-D61E94FE-8577-4FAE-AA63-2E82873E35D6Q53416548-DBD4FC26-3F29-4011-B8DE-FEA6A94B1244Q58073496-4C7ACC01-0309-4CC6-A15D-7ACEC609EF3EQ58591943-AB1C4612-EBB2-4953-A3B7-52D555234D60Q58705140-79954611-9DDD-4A65-ABBE-7AE1CD781929Q58708466-7DFF9BD0-D72A-4F3A-A0A5-1D336A312D91Q58786646-01CCC659-0D7D-47F2-B0C5-EE2D06016F9DQ59133970-0DE867E9-1EA7-4A4D-B81E-FF00A477C824
P2860
Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Development of next-generation ...... fect: challenges and pitfalls.
@en
type
label
Development of next-generation ...... fect: challenges and pitfalls.
@en
prefLabel
Development of next-generation ...... fect: challenges and pitfalls.
@en
P2093
P2860
P1476
Development of next-generation ...... fect: challenges and pitfalls.
@en
P2093
Hideaki Nakamura
Hiroshi Maeda
P2860
P356
10.1517/17425247.2014.955011
P407
P577
2014-11-26T00:00:00Z